The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma (TRIPP-FFX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05466799
Recruitment Status : Recruiting
First Posted : July 20, 2022
Last Update Posted : April 11, 2024
Information provided by (Responsible Party):
OncoSil Medical Limited

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : September 2024